JP2022525425A - アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法 - Google Patents

アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法 Download PDF

Info

Publication number
JP2022525425A
JP2022525425A JP2021556402A JP2021556402A JP2022525425A JP 2022525425 A JP2022525425 A JP 2022525425A JP 2021556402 A JP2021556402 A JP 2021556402A JP 2021556402 A JP2021556402 A JP 2021556402A JP 2022525425 A JP2022525425 A JP 2022525425A
Authority
JP
Japan
Prior art keywords
abiraterone
pharmaceutical
crystalline
patient
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525425A5 (https=
Inventor
デイブ ミラー
アーヴィ ガラ
ロバート オー． ザ サード ウィリアムズ
アンジェラ スパンジェンバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022525425A publication Critical patent/JP2022525425A/ja
Publication of JP2022525425A5 publication Critical patent/JP2022525425A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021556402A 2019-03-18 2020-03-17 アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法 Pending JP2022525425A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820076P 2019-03-18 2019-03-18
US62/820,076 2019-03-18
US201962942111P 2019-11-30 2019-11-30
US62/942,111 2019-11-30
PCT/US2020/023066 WO2020190900A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Publications (2)

Publication Number Publication Date
JP2022525425A true JP2022525425A (ja) 2022-05-13
JP2022525425A5 JP2022525425A5 (https=) 2023-03-27

Family

ID=72521270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556402A Pending JP2022525425A (ja) 2019-03-18 2020-03-17 アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法

Country Status (9)

Country Link
US (1) US20220362264A1 (https=)
EP (1) EP3941478A4 (https=)
JP (1) JP2022525425A (https=)
CN (1) CN113825514A (https=)
AU (1) AU2020240017A1 (https=)
BR (1) BR112021018540A2 (https=)
CA (1) CA3133620A1 (https=)
IL (1) IL286416A (https=)
WO (1) WO2020190900A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514707A (ja) * 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514707A (ja) * 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANO, H., ET AL., AAPS PHARMSCITECH, vol. 11, no. 2, JPN6023052123, 2010, pages 885 - 893, ISSN: 0005364817 *

Also Published As

Publication number Publication date
AU2020240017A1 (en) 2021-11-04
US20220362264A1 (en) 2022-11-17
BR112021018540A2 (pt) 2021-11-30
WO2020190900A1 (en) 2020-09-24
EP3941478A1 (en) 2022-01-26
IL286416A (en) 2021-10-31
EP3941478A4 (en) 2022-12-28
WO2020190900A8 (en) 2021-10-14
CN113825514A (zh) 2021-12-21
CA3133620A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP2023182674A (ja) アビラテロン環状オリゴマー薬学的製剤ならびにその形成法および投与法
JP6697473B2 (ja) 酢酸アビラテロンの複合体、その製造のための方法、およびそれらを含有する医薬組成物
CN102813663B (zh) 包含四氢叶酸的药物组合物
JP2010525082A (ja) 固体投与形
EP2101735A2 (en) Nanoparticulate formulations and methods for the making and use thereof
CN106265580A (zh) Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
EP3938368B1 (en) Compound form having enhanced bioavailability and formulations thereof
WO2015032873A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate
Gala et al. The effect of drug loading on the properties of abiraterone–hydroxypropyl beta cyclodextrin solid dispersions processed by solvent free KinetiSol® technology
US20220401579A1 (en) Inclusion complexes of pharmaceuticals and cyclic oligomers
JP2022525425A (ja) アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法
HUP1000327A2 (en) Composition containing nanostructured ezetibime and process for it's preparation
WO2023078265A1 (zh) 一种固体分散体、其制备方法及包含其的固体制剂
CN101094656A (zh) 含低剂量雌二醇的口服固体剂型
Choudhari et al. Engineering Amorphous Solid Dispersions of Abiraterone Acetate via HPMC HME: A Polymer-Centric Hot-Melt Extrusion Strategy for Formulation-Driven Bioavailability Improvement.
EA046804B1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы
WO2021209945A1 (en) Methods and compositions for treating prostate cancer
AU2013202756B2 (en) Pharmaceutical composition containing a tetrahydrofolic acid
HK40065292B (en) Compound form having enhanced bioavailability and formulations thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240708